TP53 and acute myeloid leukemia: These included patient 4 (BPDCN patient with entirely extramedullary disease relapse) who achieved a PET-negative CR (confirmed by tumor site biopsy) (Figure 1C), while patient 2 (with MDS and multiple pathogenic mutations) and patient 3 (with AML and pathogenic TP53 mutation) had no detectable residual disease by next-generation sequencing after CIML NK cell therapy (Figure 1D).